pancreatic-ductal-adenocarcinoma

Documents about pancreatic-ductal-adenocarcinoma

• Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma#1140527ClinicalTrials.gov
• PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)#982636ClinicalTrials.gov
• Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)#835494ClinicalTrials.gov
• Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment#1164739ClinicalTrials.gov
• Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer#905994ClinicalTrials.gov
• Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma#874128ClinicalTrials.gov
• Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma#911402ClinicalTrials.gov
• Hedgehog Inhibition for Pancreatic Ductal Adenocarcinoma (PDAC) in the Preoperative Setting (HIPPoS)#1114360ClinicalTrials.gov
• Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma#849550ClinicalTrials.gov
• Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma#353294ClinicalTrials.gov
• How Does Pre-operative Biliary Drainage in Pancreatic Adenocarcinoma Affect Surgical Outcomes in Pancreatic Cancer Surgery#840624ClinicalTrials.gov
• Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer#884408ClinicalTrials.gov
• A Prospective Registry for Patients at High-Risk for Pancreatic Cancer#915712ClinicalTrials.gov
• Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma#966828ClinicalTrials.gov
• Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma#870632ClinicalTrials.gov
• Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )#1397286ClinicalTrials.gov
• Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma#860721ClinicalTrials.gov
• Nab-pacliatxel Plus Gemcitabine in Korean Patients With Metastatic Pancreatic Ductal Adenocarcinoma#1100425ClinicalTrials.gov
• Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis#884239ClinicalTrials.gov
• Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma#1125415ClinicalTrials.gov
• A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients with Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma#1410331ClinicalTrials.gov
• The HELPP Score: A Pretreatment Score to Predict Survival in Pancreatic Cancer#1074692ClinicalTrials.gov
• PRaG Therapy in Combination With Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) (NeoPRAG Study)#842223ClinicalTrials.gov
• AI Derived Biomarker to Select Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma#966162ClinicalTrials.gov
• Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma#1320459ClinicalTrials.gov
• Expanded Access to Mifomelatide for Cachexia in Adults With Advanced PDAC#883352ClinicalTrials.gov
• Observational Registry Evaluating the Clinical Impact of the Blood-Based Biomarker Test for Early-Stage Pancreatic Ductal Adenocarcinoma#855552ClinicalTrials.gov
• Hyperpolarized 13C Pyruvate MRI for Treatment Response Assessment in Pancreatic Ductal Adenocarcinoma#890882ClinicalTrials.gov
• Prospective Evaluation of MRI Biomarkers in Pancreatic Ductal Adenocarcinoma#808030ClinicalTrials.gov
• Study of a Polygenic Risk Score to Predict the Risk of Pancreatic Ductal Adenocarcinoma#1323780ClinicalTrials.gov
• Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma#1195219ClinicalTrials.gov
• Synergistic Immunomodulatory Effect of Synbiotics Pre and Postoperative Resection of Pancreatic Ductal Adenocarcinoma#1382902ClinicalTrials.gov
• Pancreaticoduodenectomy in Elderly Pancreatic Ductal Adenocarcinoma Patients#1408811ClinicalTrials.gov
• Magnetic Resonance Imaging (MRI) to Predict Outcomes of Pancreatic Ductal Adenocarcinoma (PDAC)#1436974ClinicalTrials.gov
• OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma#908650ClinicalTrials.gov
• PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma#1093477ClinicalTrials.gov
• Clinical Significance of a Cell-Of-Origin-Based Classification in Pancreatic Ductal Adenocarcinoma#1347129OKAYAMA UNIVERSITY SCIENTIFIC ACHIEVEMENT REPOSITORY
• ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma#405139ClinicalTrials.gov
• Phase I Study of Cosibelimab and Balixafortide in Metastatic Pancreatic Ductal Adenocarcinoma#1183563ClinicalTrials.gov
• RPSA as a Potential Prognostic Biomarker of Pancreatic Cancer#873882ClinicalTrials.gov
• Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis#1045021ClinicalTrials.gov
• Pancreatic Adenocarcinoma Signature Stratification for Treatment#1245183ClinicalTrials.gov
• The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma#67834ClinicalTrials.gov
• Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer#869697ClinicalTrials.gov
• Predictive Factors for Resection and Survival in Type A Borderline Resectable Pancreatic Ductal Adenocarcinoma Patients After Neoadjuvant Therapy#865049ClinicalTrials.gov
• ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma.#349977ClinicalTrials.gov
• Icaritin in Combination With AG in Patients With Previously Untreated Advanced Pancreatic Ductal Adenocarcinoma#870526ClinicalTrials.gov
• NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial#1394645ClinicalTrials.gov
• Nab-Paclitaxel + Cisplatin + Gemcitabine in Untreated Metastatic Pancreatic Adenocarcinoma#862366ClinicalTrials.gov
• Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma#1096251ClinicalTrials.gov